PSMA
Assets acting on this target.
- Class
- PSMA-targeted
Related mechanisms
PSMA drugs compared
5 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| 225Ac-PSMA-617 | Novartis | radioligand therapy (actinium-225) | Phase 3 | Phase 3 in Prostate Cancer |
| HRS-4357 | Jiangsu Hengrui Pharmaceuticals | undisclosed | Phase 3 | Phase 3 in Metastatic Castration-Resistant Prostate Cancer |
| Zadavotide guraxetan | AstraZeneca | radioconjugate (actinium-225) | Phase 3 | Phase 3 in Metastatic Castration-Resistant Prostate Cancer |
| HRS-1738 | Jiangsu Hengrui Pharmaceuticals | undisclosed | Phase 1/2 | Phase 1/2 in Prostate Cancer |
| SHR-4394 | Jiangsu Hengrui Pharmaceuticals | antibody-drug conjugate | Phase 1/2 | Phase 1/2 in Prostate Cancer |